Progenics Sends Letter to Shareholders
October 09, 2019 16:30 ET
|
Progenics Pharmaceuticals Inc.
Highlights Clear and Compelling Value of Lantheus Transaction to All Shareholders Urges Shareholders to Prevent Velan and its Nominees from Seizing Control of the Board and Company without a Premium...
Progenics Confirms Notice of Preliminary Consent Solicitation by Velan Capital, L.P. Despite Repeated Efforts by the Company to Reach a Reasonable Resolution
September 18, 2019 16:59 ET
|
Progenics Pharmaceuticals Inc.
Board Has Made Numerous Corporate Governance Enhancements Reflecting Feedback From Shareholders No Shareholder Action Required at this Time NEW YORK, Sept. 18, 2019 (GLOBE NEWSWIRE) --...
Progenics Pharmaceuticals Announces Presentation at the International Conference on Immunotherapy Radiotherapy Combinations
September 03, 2019 08:30 ET
|
Progenics Pharmaceuticals Inc.
NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
Progenics Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update
August 09, 2019 07:30 ET
|
Progenics Pharmaceuticals Inc.
Recorded First Revenues for AZEDRA®; CMS Grants New Technology Add-On Payment of Up to $98,150 per Therapeutic Dose for Inpatient Use of AZEDRAEnrollment Completed Ahead of Schedule in Phase 3 CONDOR...
Progenics Pharmaceuticals Announces Additional Governance Enhancements
August 08, 2019 08:00 ET
|
Progenics Pharmaceuticals Inc.
Board Accepts Resignations of Directors Peter J. Crowley and Michael D. Kishbauch,Effective October 17, 2019 Board Names New Committee Chairs Board Adopts Stock Ownership Guidelines for Directors...
CMS Grants New Technology Add-On Payment for Inpatient Use of AZEDRA® (iobenguane I 131)
August 06, 2019 08:30 ET
|
Progenics Pharmaceuticals Inc.
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
Progenics Pharmaceuticals Completes Enrollment in Pivotal Phase 3 CONDOR Study of PyL for the Detection of Prostate Cancer
August 05, 2019 08:30 ET
|
Progenics Pharmaceuticals Inc.
Top-line Data Now Expected by Year End Reaches Alignment with FDA on Regulatory Path; Company to Submit NDA Following Positive CONDOR Data Completed Enrollment in Pivotal Phase 3 Trial in...
Progenics Pharmaceuticals Sets Second Quarter 2019 Financial Results and Business Update Call for August 9
August 01, 2019 08:30 ET
|
Progenics Pharmaceuticals Inc.
NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
Progenics Pharmaceuticals Announces Collaboration with Veterans Affairs on the AI Research Program for Medical Image Analysis
July 25, 2019 08:30 ET
|
Progenics Pharmaceuticals Inc.
NEW YORK and WASHINGTON, July 25, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and...
Progenics Announces Preliminary Voting Results of Annual Meeting of Shareholders
July 12, 2019 09:11 ET
|
Progenics Pharmaceuticals Inc.
NEW YORK, July 12, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...